Emerging Treatments in Breast Cancer: Are Antibody Drug Conjugates Here to Stay?
Emerging Treatments In Breast Cancer: Are Antibody Drug Conjugates Here to Stay? from Patient Empowerment Network on Vimeo.
What’s the latest breast cancer news from research studies? Expert Dr. Demetria Smith-Graziani shares research updates she’s most excited about and proactive advice for patients to stay knowledgeable about care options.
Demetria Smith-Graziani, MD, MPH is an Assistant Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. Learn more about Dr. Smith-Graziani.
[ACT]IVATION TIP
“...ask their oncologist what the recent updates in medical advancements and oncology treatments are.”
Download Guide | Descargar Guía en Español
See More from [ACT]IVATED Breast Cancer
Related Resources:
 |
 |
What Treatments Are Available for HER2-Positive Metastatic Breast Cancer? |
Transcript:
Lisa Hatfield:
Dr. Smith, what breast cancer data or studies are coming out of major medical conferences like ASCO that you’re most excited about? And can you speak to the challenge and promise or hope of these emerging treatments?
Dr. Demetria Smith-Graziani:
Sure, so it’s been a really exciting past few years for breast cancer, there have been a lot of new treatments that have developed quite recently, I am particularly excited about hearing about the newest, what we call antibody drug conjugates, and those are medications that have an antibody that can bind to specific proteins found on cancer cells, so they can target cancer cells. But they also have chemotherapy attached to them, and that way they’re able to deliver that chemotherapy specifically to the cancer cells in a more targeted fashion as opposed to delivering chemotherapy to all the cells in your body.
We’ve already had a number of approvals for very effective antibody drug conjugates for different types of breast cancer, and I look forward to seeing newer versions of antibody drug conjugates and also new uses for already existing antibody drug conjugates. I’m also excited to see what new information we have about ways to reduce or eliminate disparities in breast cancer outcomes, because we have done a lot in recent years of describing the issues with disparities, of acknowledging that they exist, but what’s still left to be done is figuring out what are the best strategies to actually get rid of those disparities. So I’m looking forward to seeing what people propose as possible solutions to that problem, and my activation tip for patients is to ask their oncologist what the recent updates in medical advancements and oncology treatments are.
Share Your Feedback:
Create your own user feedback survey
